In most cases, requiring members to enroll in a lifestyle modification program or limiting the prescribing of the drugs to certain specialists would result in a loss of rebates for GLP-1s for weight loss
The FDA proposed on April 30, 2026 to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs
A Brave New World: Therapeutic Area Deep Dives on Obesity Related solutions Data, AI, and expertise empower Commercial Solutions to optimize strategy, accelerate market access, and maximize brand performance
The immunology of psoriasis-current concepts in pathogenesis
This medication can prevent severe diabetes complications, such as kidney damage and blindness, and can also reduce the risk of heart attack and stroke when diabetes is properly managed
In short: in the lab, BPC157 often looks benign